 |
Among the largest 'Vertically Integrated' pharmaceutical companies in India, Aurobindo has robust product portfolio spread over major product areas encompassing CVS, CNS, Anti-Retroviral, Antibiotics, Gastroenterologicals, Anti-Diabetics and Anti-Allergic with approved manufacturing facilities by USFDA, UKMHRA, WHO, MCC-SA, ANVISA-Brazil for both APIs & Formulations and has Global presence with own infrastructure, strategic alliances, subsidiaries & joint ventures. |
|
Aurobindo’s R & D strengths lie in developing intellectual property in non-infringing processes and resolving complex chemistry challenges. In the process, Aurobindo develops new drug delivery systems, dosage formulations and applies new technology for better processes. |
|
|
 |
|
|
|
| 13 - 15 October ’09 :- | CPhI-World 2009 in Madrid, Spain at Stall No. 10:E10 |
| 1 - 3 December ’09 :- | CPhI-India 2009 in Mumbai at Stall No. 1:I5 |
|
Important Mile Stones
 |
Merger of APL Life Sciences Ltd & Senor Organics Pvt. Ltd. |
|
Issue of USD 200 Million FCCBs |
|
Achieved Turnover of Rs.23 billion |
|
Establishment of a WOS for Research activities |
| more >> |
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
Stock Prices - June 2009 |
|
|
| STOCK EXCHANGE |
OPEN |
HIGH |
LOW |
CLOSE |
VOLUME TRADED |
| BSE |
403.00 |
528.00 |
374.00 |
465.50 |
12,73,007 |
| NSE |
399.90 |
529.00 |
374.00 |
465.65 |
44,09,220 |
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
 |
 |
| Aurobindo's R & D strengths lie in developing intellectual property in non-infringing processes and resolving complex chemistry challenges. |
|
|
 |
|
|
|
|
| |
 |
 |
|
|
 |
|
|
|
|
|
|
